logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Ariad Pharmaceuticals (ARIA) Spikes on Eli Lilly (LLY) Buyout Rumors

By  +Follow January 23, 2014 12:57PM
Share:
Tickers Mentioned:

Rumors that major pharmaceutical companies may be circling Ariad Pharmaceuticals (ARIA) regarding a potential buyout helped drive shares of the volatile stock higher on Thursday. Ariad was up over 11 percent Thursday on extremely heavy volume, continuing Ariad’s bigs swings that have come to characterize the stock in recent months.

Ariad Buyout Rumors Spark Run

The inciting incident for today’s gain appears to be an article that appeared in the Daily Mail that speculated that several major buyers could be interesting in buying Ariad. The article states that Eli Lilly (LLY) , GlaxoSmithKline (GSK) , and Shire (SHPG) are all interested in purchasing the company following the approval of Iclusig (a pill form of Ponatinib treatment) for treatment of leukemia patients.

The frontrunner is reportedly Eli Lilly, who may be willing to pay as much as $20 a share. That would take the price close to the share value in October prior to a massive plunge following serious regulatory concerns.

Could Ariad’s Wild Ride Finally be Coming to a Close?

Ariad Pharmaceuticals has been on a long, wild ride that has taken shares from a 52-week high of $23 a share, to $22.50 a share in October before the FDA put a hold on Iclusig because of worries about blood clots. That sent shares plummeting to the 52-week low of just $2.15 a share. Shares continued to exhibit big volatility on heavy volume over the next month, with double-digit swings in a single day not at all out of the norm.

However, things started to stabilize for Ariad after the FDA approved Iclusig again with new prescribing guidelines. Now, Ariad’s been making steady gains since mid-December and appears to have left the worst behind it.

What the future holds for Ariad is still far from clear, and the fact that the stock is trading at under $7.50 a share should prove that a certain healthy skepticism of the $20 a share price quoted in the buyout rumors.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

				
				
By  +Follow January 23, 2014 12:57PM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Beyond Twitter: 5 Small-Cap Tech Plays Nobody’s Talking About


Will the Fed Continue Its Track Record of Unprecedented Moves?

Facebook versus Google: Who Rules the Internet?

Are These the Worst Business Documentaries on Netflix?


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN